文献速递免疫规划卫生政策与健康促进

美国商业保险人群中疫苗安全监测相关结局的背景发生率

Incidence of outcomes relevant to vaccine safety monitoring in a US commercially-insured population.
PubMed 文献 · Vaccine · 2018-11-15

结果显示不同结局定义下发生率差异很大,19种结局(59%)的特异定义发生率不足敏感定义的一半,神经及血液/肾脏结局尤为明显;发生率常以女性、≥65岁和IPD高风险者最高。

要点

  • 同一结局采用敏感与特异定义时背景发生率可相差较大,特异定义发生率可不足敏感定义的一半。
  • 神经及血液/肾脏结局对定义尤其敏感,特异与敏感发生率平均比值分别为0.30和0.26。
  • 背景发生率常以女性、≥65岁和IPD高风险人群更高,应按亚组分层解读。

核心结论

  • 美国商业保险人群中32种疫苗安全相关结局的背景发生率随结局定义和人群亚组而变化。

研究设计与样本

  • 回顾性队列研究,纳入2007年1月至2014年8月美国商业健康计划中6-100岁、参保≥12个月且无既往肺炎球菌疫苗接种者。

主要发现

  • 神经及血液/肾脏结局的定义间差异较大,特异与敏感发生率平均比值分别为0.30和0.26。
  • 32种结局的发生率常以女性、≥65岁和IPD高风险者最高。

关键数值与推荐

  • 对32种心脏、代谢、过敏、自身免疫、神经、血液和肾脏结局分别制定敏感定义与特异定义,特异定义要求有与结局一致的额外医疗证据。
  • 发生率以每10万人年表示,并按年龄、性别和IPD风险类别分层。

临床怎么用

  • 评估肺炎球菌疫苗安全信号时需注意病例定义对背景发生率的影响,神经及血液/肾脏结局可能需更精细定义和病历验证。

局限性

  • 原文摘要未报告具体局限性。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

BACKGROUND: Background incidence rates (IRs) of potential safety outcomes among vaccine eligible individuals can inform assessment of vaccine safety. Vaccine safety surveillance often uses claims databases, but the impact of outcome definitions on background IR estimates is largely unexplored. Using two definitions for each outcome, we estimated background IRs of 32 cardiac, metabolic, allergic, autoimmune, neurologic, hematologic and nephrologic outcomes among individuals eligible to receive pneumococcal vaccination. METHODS: We defined a cohort of individuals aged 6-100 years in US commercial health plans who had ≥12 months of health plan enrollment between January 2007 and August 2014 and no previous record of conjugate or simple polysaccharide pneumococcal vaccination. We developed a sensitive and a specific definition for each outcome, with the specific definition requiring evidence of additional care consistent with the outcome. IRs per 100,000 person-years for each outcome were presented overall and stratified by age, gender, and invasive pneumococcal disease (IPD) risk category. RESULTS: We followed 19.9 million individuals for a median of 2.5 years. Wide variation was seen in IRs across different definitions of the 32 outcomes, with 19 (59%) outcomes having a specific definition IR less than half of the sensitive definition IR. IRs were particularly variable by definition for outcomes categorized as either hematologic/nephrologic or neurologic (mean ratio of specific IR to sensitive IR = 0.26 and 0.30, respectively). Across definitions, the IRs of the 32 outcomes were often highest in females, adults ≥65, and those at higher IPD risk. CONCLUSIONS: Background IRs of safety outcomes relevant to populations indicated for pneumococcal vaccine varied by outcome definitions and population subgroups in this large US commercially-insured population. Given large differences in estimated IRs using sensitive versus specific case definitions, neurologic, and hematologic/nephrologic safety outcomes as compared to allergic and autoimmune outcomes may warrant more refined definitions and medical record validation.

来源:Vaccine,查看原文。版权归原作者所有。

引用

  1. Esposito D, Titievsky L, Beachler DC, et al. Incidence of outcomes relevant to vaccine safety monitoring in a US commercially-insured population. Vaccine. 2018. PMID: 30448335. doi:10.1016/j.vaccine.2018.10.052

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。